20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      La articulación público-privada en la producción de vacunas en México Translated title: Public-private articulation in the production of vaccines in Mexico

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN El artículo analiza el proceso de privatización de la atención a la salud: la Articulación Público-Privada (APP). Específicamente estudia la producción de vacunas em México, tomando como caso los Laboratorios de Biológicos y Reactivos de México, S.A. de C.V. (Birmex), empresa paraestatal, responsable de producir, distribuir e investigar biológicos y reactivos en México. Interesa destacar el comportamiento de Birmex durante el periodo de la pandemia de influenza de 2009, producida por el virus de la influenza A subtipo H1N1. Los resultados muestran que gracias al impulso de las políticas de liberalización y desregulación, existe una apertura de los servicios públicos a las corporaciones supranacionales.

          Translated abstract

          ABSTRACT This paper analyzes the process of privatization of health care services through the Public-Private Articulation (APA). The production of vaccines in Mexico is studied, through the case study of Biological and Reagents Laboratories of Mexico, LLC (Birmex), company responsible for the production, distribution and investigation of biological and reagents in Mexico. It points out specially Birmex’s performance during the period of pandemic influenza A virus, H1N1 subtype. The results show that there exists opening of the public services to supranational corporations encouraged by policies of liberalization and deregulation.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City

          Objective To evaluate the association of 2008-9 seasonal trivalent inactivated vaccine with cases of influenza A/H1N1 during the epidemic in Mexico. Design Frequency matched case-control study. Setting Specialty hospital in Mexico City, March to May 2009. Participants 60 patients with laboratory confirmed influenza A/H1N1 and 180 controls with other diseases (not influenza-like illness or pneumonia) living in Mexico City or the State of Mexico and matched for age and socioeconomic status. Main outcome measures Odds ratio and effectiveness of trivalent inactivated vaccine against influenza A/H1N1. Results Cases were more likely than controls to be admitted to hospital, undergo invasive mechanical ventilation, and die. Controls were more likely than cases to have chronic conditions that conferred a higher risk of influenza related complications. In the multivariate model, influenza A/H1N1 was independently associated with trivalent inactivated vaccine (odds ratio 0.27, 95% confidence interval 0.11 to 0.66) and underlying conditions (0.15, 0.08 to 0.30). Vaccine effectiveness was 73% (95% confidence interval 34% to 89%). None of the eight vaccinated cases died. Conclusions Preliminary evidence suggests some protection from the 2008-9 trivalent inactivated vaccine against pandemic influenza A/H1N1 2009, particularly severe forms of the disease, diagnosed in a specialty hospital during the influenza epidemic in Mexico City.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            El Universal

              Bookmark
              • Record: found
              • Abstract: not found
              • Book: not found

              Health Systems Financing: The Path to Universal Coverage.

                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                sdeb
                Saúde em Debate
                Saúde debate
                Centro Brasileiro de Estudos de Saúde (Rio de Janeiro, RJ, Brazil )
                0103-1104
                2358-2898
                December 2016
                : 40
                : 111
                : 9-21
                Affiliations
                [2] Xochimilco orgnameUniversidad Autónoma Metropolitana orgdiv1División de Ciencias Biológicas y de Salud orgdiv2Departamento de Atención a la Salud Mexico ceibenschutz@ 123456yahoo.com.mx
                [3] Xochimilco orgnameUniversidad Autónoma Metropolitana orgdiv1División de Ciencias Biológicas y de Salud orgdiv2Departamento de Atención a la Salud Mexico xarenizafra@ 123456gmail.com
                [1] Xochimilco orgnameUniversidad Autónoma Metropolitana orgdiv1División de Ciencias Biológicas y de Salud orgdiv2Departamento de Atención a la Salud Mexico stamez@ 123456correo.xoc.uam.mx
                [4] Xochimilco orgnameUniversidad Autónoma Metropolitana orgdiv1División de Ciencias Biológicas y de Salud orgdiv2Departamento de Atención a la Salud Mexico raqueluamxoc@ 123456gmail.com
                Article
                S0103-11042016000400009
                10.1590/0103-1104201611101
                2519b2ec-f89c-4197-b5d8-3b52275a777c

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : April 2016
                : October 2016
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 25, Pages: 13
                Product

                SciELO Brazil


                Asociaciones entre el sector público y el privado,Subtipo H1N1 del virus de la influenza A,Vacunas contra la influenza,Public-private sector partnerships,Influenza A virus, H1N1 subtype,Influenza vaccines

                Comments

                Comment on this article